IP Group (LON:IPO – Get Free Report) released its quarterly earnings data on Tuesday. The company reported GBX 3.53 earnings per share (EPS) for the quarter, Digital Look Earnings reports. IP Group had a return on equity of 14.25% and a net margin of 321.64%.
Here are the key takeaways from IP Group’s conference call:
- NAV per share rose 3.2% to 114p at June 30 and approximately 117p by September 11, while gross cash reached about £239 million. Portfolio companies also raised more than £500 million from third parties, providing external validation of their progress.
- Pfizer’s obesity programs continued to de-risk, with the royalty asset’s carrying value increasing by £27 million to roughly £153 million after the amylin combination entered Phase IIb. Berobenatide Phase III recruitment is reportedly close to completion, supporting a potential 2028 launch, although clinical, regulatory and commercial risks remain.
- Cash realizations were strong at £69 million in the first half and approximately £86 million year to date, taking cumulative proceeds since the start of 2025 to £154 million. Management remains confident in reaching its £250 million realization target by the end of 2027.
- Oxford Nanopore reported 12% constant-currency revenue growth, a 400-basis-point gross-margin improvement and an adjusted EBITDA loss that more than halved. It remains on track for EBIT break-even in 2027 and positive free cash flow in 2028, supported by a new cross-licensing agreement with $35 million of committed revenue plus royalties.
- Management acknowledged that the shares continue to trade at roughly a 40% discount to NAV and said reducing the gap will require sustained NAV growth, more realizations and shareholder-focused capital allocation. Around £50 million is available for potential shareholder returns, but the timing and form of any action have not been decided.
IP Group Price Performance
IP Group stock traded down GBX 0.20 during midday trading on Friday, reaching GBX 69.80. 4,432,854 shares of the stock traded hands, compared to its average volume of 6,930,408. The company has a quick ratio of 8.59, a current ratio of 36.57 and a debt-to-equity ratio of 11.90. IP Group has a 12 month low of GBX 48 and a 12 month high of GBX 75. The stock’s fifty day moving average is GBX 68.03 and its 200-day moving average is GBX 63.22. The stock has a market cap of £616.63 million, a P/E ratio of 9.83 and a beta of 1.27.
Insider Buying and Selling
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 110 price target on shares of IP Group in a research note on Wednesday. Berenberg Bank reissued a “buy” rating and issued a GBX 119 price objective on shares of IP Group in a report on Tuesday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of GBX 114.50.
Get Our Latest Research Report on IP Group
About IP Group
IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.
Further Reading
- Five stocks we like better than IP Group
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for IP Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IP Group and related companies with MarketBeat.com's FREE daily email newsletter.
